Keyword: Tokai Pharmaceuticals
Biopharma executives share how they manage outsourcing relationships at this year's Drug Development Forum.
University of Michigan researchers have identified a large molecule that selectively attacks prostate tumors without harming healthy cells.
With a sense of inevitability, microcap Tokai, besieged by weak trial results and a slew of axed staffers in its wake, is considering all options as its future hangs in the balance.
Microcap Tokai has had a summer to forget, but its woes got worse this week as it announced that it will stop enrollment in one trial and ax another as its future appears in jeopardy.
A week after microcap Tokai saw its shares plummet after the failure of its key Phase III prostate cancer candidate galeterone, the biotech has unsurprisingly announced major cuts across its company.
Tokai had hoped that its prostate cancer candidate could best Medivation’s Xtandi, but now the microcap biotech has instead discontinued that Phase III pivotal trial due to disappointing data.